School of Medicine, Tehran University of Medical Sciences, IR.
Swiss Med Wkly. 2011 Jul 30;141:w13239. doi: 10.4414/smw.2011.13239. eCollection 2011.
Evaluating the effects of a commercially available synbiotic preparation (contains both prebiotic and probiotic elements) on functional constipation in males.
In a randomised controlled trial, a total of 66 adult men with functional constipation were equally allocated to receive a synbiotic mixture or a placebo. The synbiotic mixture or placebo was given as capsules with the same shape and colour, and patients received the capsules twice a day for 4 weeks.
A total of 60 patients (31 in the synbiotic group) completed the study. At baseline evaluation, there was no significant difference between the mean stool frequency per week in synbiotic and placebo groups [mean difference of 0.11 times (95% CI: -0.31-0.55), p = 0.58]. However, mean stool frequency increased significantly at weeks 2 [mean difference of 1.32 times (95% CI: 0.21-2.43)] and 4 [mean difference of 1.58 times (95% CI: 0.18-2.99)] in the synbiotic group compared with the placebo group (p = 0.02). A significant difference (p = 0.006) was found at weeks 2 [mean difference of 0.83 (95% CI: 0.20-1.45)] and 4 [mean difference of 0.91 (95% CI: 0.3-1.51)] between the synbiotic and placebo groups regarding the Bristol stool form score. No adverse effect was seen in the synbiotic group.
The results of this study indicated that this specific commercial product seemed to be effective in increasing stool frequency and improving consistency in this sample of males with functional constipation. However, further studies with longer follow ups, and including females and elderly patients are required to confirm the efficacy of this product for treatment of functional constipation.
评估一种市售的合生元制剂(含有益生元和益生菌成分)对男性功能性便秘的影响。
在一项随机对照试验中,共有 66 名成年男性功能性便秘患者被平均分为接受合生元混合物或安慰剂组。合生元混合物或安慰剂以相同形状和颜色的胶囊形式给予,患者每天服用两次,持续 4 周。
共有 60 名患者(合生元组 31 名)完成了研究。基线评估时,合生元组和安慰剂组每周平均排便次数无显著差异[平均差异 0.11 次(95%CI:-0.31-0.55),p = 0.58]。然而,与安慰剂组相比,合生元组在第 2 周[平均差异 1.32 次(95%CI:0.21-2.43)]和第 4 周[平均差异 1.58 次(95%CI:0.18-2.99)]时平均排便次数显著增加(p = 0.02)。在第 2 周[平均差异 0.83(95%CI:0.20-1.45)]和第 4 周[平均差异 0.91(95%CI:0.3-1.51)],合生元组和安慰剂组之间的布里斯托粪便形态评分存在显著差异(p = 0.006)。合生元组未出现不良反应。
本研究结果表明,这种特定的商业产品似乎在增加粪便频率和改善该样本中男性功能性便秘的一致性方面有效。然而,需要进一步进行随访时间更长的研究,并包括女性和老年患者,以确认该产品治疗功能性便秘的疗效。